Novel prodrug supramolecular nanoparticles capable of rapid mitochondrial-targeting and ROS-responsiveness for pancreatic cancer therapy

Mitochondrial dysfunction is a feature of cancer cells and targeting cancer mitochondria has emerged as a promising anticancer therapy.